Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 ...
Acrivon Therapeutics reports 62.5% confirmed ORR in OncoSignature-positive endometrial cancer patients from ACR-368 Phase 2 trial, with significant responder segregation (p=0.009) and median duration of response not yet reached (~6 months). FDA clears IND for ACR-2316, with first-in-human dosing expected Q4 2024. AP3 Interactome platform generates proprietary insights for drug development.
Reference News
Acrivon Therapeutics reports 62.5% confirmed ORR in OncoSignature-positive endometrial cancer patients from ACR-368 Phase 2 trial, with significant responder segregation (p=0.009) and median duration of response not yet reached (~6 months). FDA clears IND for ACR-2316, with first-in-human dosing expected Q4 2024. AP3 Interactome platform generates proprietary insights for drug development.